AEON Biopharma Q2 net loss narrows on warrant gain; cash runway extended
AEON•Financing extends cash runway
The U.S. biopharmaceutical company said it completed $15.3 million in financing, which it expects will extend its cash runway into Q1 2027, including the July financing proceeds.
Q2 loss narrows on warrant gain
AEON Biopharma said its second-quarter net loss narrowed to $1.16 million, or $0.02 per share, from a larger loss a year earlier, helped by a $4.9 million gain from a change in the fair value of warrants.
The company also reported Q2 EBIT of -$5.92 million and pretax loss of $1.16 million.
Program progress and listing compliance
AEON said it continued advancing its ABP-450 biosimilar program and received FDA feedback supporting its analytical development approach.
The company said it presented data at medical conferences supporting analytical similarity between ABP-450 and onabotulinumtoxinA.
After quarter-end, AEON said it restored compliance with NYSE American listing requirements.
